Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumors 483Solid Tumor 446Advanced Solid Tumor 414Unspecified Adult Solid Tumor, Protocol Specific 362Solid Tumors 336Mesothelioma, Malignant 324Mesothelioma 289Solid Tumor, Adult 124Carcinoma, Non-Small-Cell Lung 122Retinoblastoma 117Lung Neoplasms 77Ovarian Neoplasms 75Melanoma 65Sarcoma 62Carcinoma, Renal Cell 59Stomach Neoplasms 58Pancreatic Neoplasms 58Neoplasms 53Esophageal Neoplasms 53Small Cell Lung Carcinoma 52Colorectal Neoplasms 52Hematopoietic and Lymphatic System Neoplasm 50Uterine Cervical Neoplasms 46Breast Neoplasms 46Solid Tumours 35Neoplasm Metastasis 35Advanced or Metastatic Solid Tumors 35Squamous Cell Carcinoma of Head and Neck 34Carcinoma, Hepatocellular 32Triple Negative Breast Neoplasms 31

Interventions

sotorasib 1Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
KRAS p.G12C Mutant Advanced Solid Tumors × Other solid neoplasm × Clear all
NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Amgen

Phase 1/2 Active not recruiting
713 enrolled 1 FDA
Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡